Luspatercept not checked
Celgene · BMS-986346 · ACE-536
FollowEvery change as it happens, and a Monday email
Trials
14 active
21 in total · 12 in the EU
What this is
- How it works
- A decoy protein that soaks up a signal molecule before it can reach the body's cells.-cept: receptor molecules, native or modified WHO name stem
- How it’s given
- “Luspatercept (ACE-536), an erythroid maturation agent, is a recombinant fusion protein consisting of a modified form of the extracellular domain (ECD) of the human activin receptor type IIB (ActRIIB) linked to the human immunoglobin G 1 (IgG1) Fc domain. ActRIIB receptor and its ligands are members of the transforming growth factor-β (TGF-β) superfamily. Members of the TGF-β superfamily ligands,…”In the company’s words, NCT04064060 on ClinicalTrials.gov
- Tested for
- Anemia (3 trials), Myelodysplastic Syndromes (3 trials), Beta-thalassemia (3 trials), Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Myelodysplastic Syndromes (MDS) and 1 more
- Main trialPhase 4
- “The purpose of this study is to evaluate the safety and effectiveness of luspatercept in participants who require regular blood cell transfusions due to b-thalassemia and myelodysplastic syndromes in India”In the company’s words, NCT05891249 on ClinicalTrials.gov
- Other names
- BMS-986346 · ACE-536 · REBLOZYL · ROJUZDA
Other drugs for Anemia
- NTQ5082Nanjing Chia-tai Tianqing Pharmaceutical · Phase 3
- MY008211AWuhan Createrna Science and Technology Co., Ltd · Phase 3
- 20vPCVSanofi · Phase 3
- Pneumococcal Conjugate VaccineSanofi · Phase 3
- AND017Kind Pharmaceuticals LLC · Phase 3
- CrovalimabRoche · Phase 3
Coming up5
- 16 Jul 2027Phase 2 trial completes · ClinicalTrials.gov
- 31 Jan 2028Phase 2 trial completes · ClinicalTrials.gov
- 24 Mar 2028Phase 3 trial completes · ClinicalTrials.gov
- 12 May 2028Phase 3 trial completes · ClinicalTrials.gov
- 16 Dec 2028Phase 4 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials21
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Active, not recruiting | 16 Dec 2028 | A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India | |
| Phase 3Active, not recruiting | 31 Mar 2023 | A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve | |
| Phase 3Active, not recruiting | 26 May 2025 | An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions | |
| Phase 3Active, not recruiting | 1 Oct 2025 | A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants | |
| Phase 3Active, not recruiting | 24 Mar 2028 | ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions | |
| Phase 3Recruiting | 12 May 2028 | A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials | |
| Phase 2Active, not recruiting | 1 Aug 2025 | A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia. | |
| Phase 2Active, not recruiting | 16 Jul 2027 | A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia | |
| Phase 2Recruiting | 31 Jan 2028 | Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia | |
| Phase 3Completed | 18 Jun 2019 | A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes | |
| Phase 3Completed | 5 Jan 2021 | An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia | |
| Phase 2Completed | 1 Jul 2022 | An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion | |
| Phase 2Completed | 18 Jul 2022 | A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence | |
| Phase 2Completed | 28 Nov 2022 | A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia | |
| Phase 2Completed | 29 Sep 2023 | A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions | |
| Phase 3/4Authorised | not given | Improvement of MRI assessed cerebral Perfusion and oxygenation by luspatercept-induced Anemia Correction in non-transfusion dependent Thalassemia | |
| Phase 3Ended | not given | A phase IIIb, open-label, single arm study to evaluate the efficacy and safety of luspatercept in patients with lower-risk MDS and ringsideroblastic phenotype (MDS-RS) | |
| Phase 1/2Authorised | not given | COMBOLA Trial: A randomized phase I/ II multicenter study evaluating combination of luspatercept in LR-MDS without RS having failed or being ineligible to ESA | |
| Phase 2Authorised | not given | A phase II, open-label, single arm study to evaluate the efficacy of Luspatercept in Erythropoiesis-stimulating agent naive lower-risk MDS patients with or without ring sideroblasts who do not require RBC transfusions (LENNON) | |
| Phase 2Authorised | not given | Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to Myelodysplastic Syndromes with del5q refractory/resistant/intolerant to Prior Treatments, Who Require Red Blood Cell Transfusion. | |
| Phase 2Authorised | not given | LUSPARA - A basket phase II clinical trial evaluating Luspatercept in patients affected with rare inherited anemias |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026